Inclusion Body Myositis (IBM) - Pipeline Review, H2 2020
Inclusion Body Myositis (IBM) - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis - Pipeline Review, H2 2020, provides an overview of the Inclusion Body Myositis (Musculoskeletal Disorders) pipeline landscape.
Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wrists and fingers, the muscles of the front of the thigh, and the muscles that lift the front of the foot.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Inclusion Body Myositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 2 and 5 respectively.
Inclusion Body Myositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis - Pipeline Review, H2 2020, provides an overview of the Inclusion Body Myositis (Musculoskeletal Disorders) pipeline landscape.
Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wrists and fingers, the muscles of the front of the thigh, and the muscles that lift the front of the foot.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Inclusion Body Myositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 2 and 5 respectively.
Inclusion Body Myositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Inclusion Body Myositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Inclusion Body Myositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Inclusion Body Myositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Inclusion Body Myositis (Musculoskeletal Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Inclusion Body Myositis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Inclusion Body Myositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Inclusion Body Myositis (IBM) - Overview
Inclusion Body Myositis (IBM) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Inclusion Body Myositis (IBM) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development
AAVogen Inc
Abcuro Inc
Alzheon Inc
Cleave Therapeutics Inc
Kv1.3 Therapeutics
Leadiant Biosciences Inc
Milo Biotechnology LLC
Nobelpharma Co Ltd
Orphazyme A/S
PhaseBio Pharmaceuticals Inc
Ultragenyx Pharmaceutical Inc
Inclusion Body Myositis (IBM) - Drug Profiles
ABC-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aceneuramic acid ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALZ-507 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arimoclomol citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVGN-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dalazatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DEXM-74 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene therapy To Activate Follistatin For Duchenne Muscular Dystrophy, Becker Muscular Dystrophy And Inclusion Body Myositis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PB-1023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit VCP/p97 for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UX-001P - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Inclusion Body Myositis (IBM) - Dormant Projects
Inclusion Body Myositis (IBM) - Discontinued Products
Inclusion Body Myositis (IBM) - Product Development Milestones
Featured News & Press Releases
Feb 11, 2020: CytRx highlights recently published data of its licensee Orphazyme A/S Phase 2 trial of Arimoclomol in the treatment of Sporadic Inclusion Body Myositis (sIBM)
Dec 18, 2019: Orphazyme’s arimoclomol receives US fast track designation in sporadic inclusion body myositis
May 02, 2019: CytRx Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme
Apr 29, 2019: CytRx highlights enrollment completion in phase 2/3 clinical trial of Sporadic Inclusion Body Myositis conducted by Arimoclomol Licensee Orphazyme
Apr 23, 2019: Orphazyme's Phase II/III trial in sporadic Inclusion Body Myositis fully enrolled
Apr 25, 2018: New Data Supports Dalazatide from Kv 1.3 Therapeutics as a Potential Therapy for Inclusion Body Myositis
Dec 14, 2017: Orphazyme Assumes Sponsorship of Phase II/III sIBM Trial
Nov 07, 2017: Orphazyme Receives Orphan Drug Designation To Arimoclomol For Inclusion Body Myositis From The U.S. FDA
Aug 22, 2017: Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy
Nov 11, 2016: Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union
Jul 27, 2016: Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy
Mar 24, 2016: Arimoclomol shows promise in protein misfolding disease
Mar 23, 2016: New drug shows promise against muscle wasting disease
Oct 02, 2015: Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed and Accepted for Review by European Medicines Agency
May 28, 2015: Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Figures
Introduction
Global Markets Direct Report Coverage
Inclusion Body Myositis (IBM) - Overview
Inclusion Body Myositis (IBM) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Inclusion Body Myositis (IBM) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development
AAVogen Inc
Abcuro Inc
Alzheon Inc
Cleave Therapeutics Inc
Kv1.3 Therapeutics
Leadiant Biosciences Inc
Milo Biotechnology LLC
Nobelpharma Co Ltd
Orphazyme A/S
PhaseBio Pharmaceuticals Inc
Ultragenyx Pharmaceutical Inc
Inclusion Body Myositis (IBM) - Drug Profiles
ABC-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aceneuramic acid ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALZ-507 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arimoclomol citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVGN-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dalazatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DEXM-74 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene therapy To Activate Follistatin For Duchenne Muscular Dystrophy, Becker Muscular Dystrophy And Inclusion Body Myositis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PB-1023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit VCP/p97 for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UX-001P - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Inclusion Body Myositis (IBM) - Dormant Projects
Inclusion Body Myositis (IBM) - Discontinued Products
Inclusion Body Myositis (IBM) - Product Development Milestones
Featured News & Press Releases
Feb 11, 2020: CytRx highlights recently published data of its licensee Orphazyme A/S Phase 2 trial of Arimoclomol in the treatment of Sporadic Inclusion Body Myositis (sIBM)
Dec 18, 2019: Orphazyme’s arimoclomol receives US fast track designation in sporadic inclusion body myositis
May 02, 2019: CytRx Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme
Apr 29, 2019: CytRx highlights enrollment completion in phase 2/3 clinical trial of Sporadic Inclusion Body Myositis conducted by Arimoclomol Licensee Orphazyme
Apr 23, 2019: Orphazyme's Phase II/III trial in sporadic Inclusion Body Myositis fully enrolled
Apr 25, 2018: New Data Supports Dalazatide from Kv 1.3 Therapeutics as a Potential Therapy for Inclusion Body Myositis
Dec 14, 2017: Orphazyme Assumes Sponsorship of Phase II/III sIBM Trial
Nov 07, 2017: Orphazyme Receives Orphan Drug Designation To Arimoclomol For Inclusion Body Myositis From The U.S. FDA
Aug 22, 2017: Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy
Nov 11, 2016: Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union
Jul 27, 2016: Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy
Mar 24, 2016: Arimoclomol shows promise in protein misfolding disease
Mar 23, 2016: New drug shows promise against muscle wasting disease
Oct 02, 2015: Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed and Accepted for Review by European Medicines Agency
May 28, 2015: Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Inclusion Body Myositis (IBM), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by AAVogen Inc, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Abcuro Inc, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Alzheon Inc, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Cleave Therapeutics Inc, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Kv1.3 Therapeutics, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Leadiant Biosciences Inc, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Milo Biotechnology LLC, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Nobelpharma Co Ltd, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Orphazyme A/S, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Ultragenyx Pharmaceutical Inc, H2 2020
Inclusion Body Myositis (IBM) - Dormant Projects, H2 2020
Inclusion Body Myositis (IBM) - Discontinued Products, H2 2020
Number of Products under Development for Inclusion Body Myositis (IBM), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by AAVogen Inc, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Abcuro Inc, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Alzheon Inc, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Cleave Therapeutics Inc, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Kv1.3 Therapeutics, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Leadiant Biosciences Inc, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Milo Biotechnology LLC, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Nobelpharma Co Ltd, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Orphazyme A/S, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2020
Inclusion Body Myositis (IBM) - Pipeline by Ultragenyx Pharmaceutical Inc, H2 2020
Inclusion Body Myositis (IBM) - Dormant Projects, H2 2020
Inclusion Body Myositis (IBM) - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Inclusion Body Myositis (IBM), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
Number of Products under Development for Inclusion Body Myositis (IBM), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
